NCT00107536View on ClinicalTrials.gov

Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions

Adult Primary Hepatocellular CarcinomaAdvanced Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver CancerRecurrent Adult Primary Liver CancerRecurrent Extrahepatic Bile Duct CancerRecurrent Gallbladder CancerUnresectable Extrahepatic Bile Duct CancerUnresectable Gallbladder Cancer

Interventions

DRUG

lapatinib ditosylate

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

43210

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00107536 - Lapatinib Ditosylate in Treating Patients With Unresectable Liver or Biliary Tract Cancer | Biotech Hunter | Biotech Hunter